Literature DB >> 20675708

Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission.

Carole Pierrot-Deseilligny Despujol1, Jacques Pouchot, Christian Pagnoux, Joël Coste, Loïc Guillevin.   

Abstract

OBJECTIVE: Although in most patients with WG, induction therapy leads to complete remission (CR), the high relapse rate remains a major problem. This study was undertaken to identify potential predictors of these relapses.
METHODS: WG outcomes of patients included in two randomized trials were analysed. Patients were categorized into a predominant form of the disease using a scoring system composed of three granulomatous criteria (ear, nose and throat manifestations; lung nodules; and orbital pseudotumour) and three vascular criteria (serum creatinine >125 µmol/l, haematuria or proteinuria and alveolar haemorrhage).
RESULTS: Among 174 patients, 152 (87%) entered CR with CSs and CYC. The risk of death was higher for the vascular form [odds ratio (OR) 3.5 (95% CI 1.1, 11.4)]. With a median follow-up of 50 months, 66 out of 152 patients experienced a relapse (5-year relapse rate: 49%). Multivariate analysis retained the following variables at diagnosis as independent predictors of relapse: specific cardiac involvement [hazard ratio (HR) 2.9 (95% CI 1.3, 6.5)], ANCA with cytoplasmic-labelling pattern (c-ANCA) [HR 2.1 (95% CI 1.1, 4.3)] and higher age [HR 1.4 (95% CI 1.1, 1.7)]. Conversely, severe renal insufficiency was associated with a lower relapse rate [HR 0.4 (95% CI, 0.2-0.8)]. Comparing predominant granulomatous vs predominant vascular disease, relapses were more frequent and earlier with decreasing risk over time.
CONCLUSIONS: Increased risk of first WG relapse after initial remission appears to be related to heart involvement, age and c-ANCA positivity at onset. Predominant granulomatous presentation disease seems to be associated with poorer outcomes after CR. These findings may help adapt treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675708     DOI: 10.1093/rheumatology/keq244

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  25 in total

Review 1.  Treatment of ANCA-associated vasculitis, where to go?

Authors:  Cees G M Kallenberg
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Cardiac Involvement in Granulomatosis with Polyangiitis.

Authors:  Lucy McGeoch; Simon Carette; David Cuthbertson; Gary S Hoffman; Nader Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel; Christian Pagnoux
Journal:  J Rheumatol       Date:  2015-05-01       Impact factor: 4.666

3.  Clinical outcomes of ANCA-associated vasculitis in elderly patients.

Authors:  Ágnes Haris; Kálmán Polner; József Arányi; Henrik Braunitzer; Ilona Kaszás; István Mucsi
Journal:  Int Urol Nephrol       Date:  2014-04-23       Impact factor: 2.370

4.  Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail.

Authors:  Ulrich Specks
Journal:  J Am Soc Nephrol       Date:  2014-10-16       Impact factor: 10.121

Review 5.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

6.  Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Authors:  Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

Review 7.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

Review 8.  Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.

Authors:  Ágnes Haris; Szilveszter Dolgos; Kálmán Polner
Journal:  Int Urol Nephrol       Date:  2016-09-26       Impact factor: 2.370

Review 9.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

10.  Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.

Authors:  Rennie L Rhee; Susan L Hogan; Caroline J Poulton; Julie Anne G McGregor; J Richard Landis; Ronald J Falk; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.